An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.
- DOI
- 10.64898/2026.09.12.26362500
- Published
- 2026 Sep 20
- Container
- medRxiv : the preprint server for health sciences
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.64898/2026.09.12.26362500,
title = {An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.},
author = {Chan N and Tang C and Biswas D and Park J and Zeng K and Cappadona J and Liu C and McMclean A and Berrevoets J and Bao L and Machura B and Gray RJ and Wang V and Witowski J and Geras KJ and Sparano JA and TAILORx Investigators},
year = {2026},
journal = {medRxiv : the preprint server for health sciences},
doi = {10.64898/2026.09.12.26362500},
url = {https://doi.org/10.64898/2026.09.12.26362500}
}RIS
TY - JOUR TI - An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial. AU - Chan N AU - Tang C AU - Biswas D AU - Park J AU - Zeng K AU - Cappadona J AU - Liu C AU - McMclean A AU - Berrevoets J AU - Bao L AU - Machura B AU - Gray RJ AU - Wang V AU - Witowski J AU - Geras KJ AU - Sparano JA AU - TAILORx Investigators PY - 2026 JO - medRxiv : the preprint server for health sciences DO - 10.64898/2026.09.12.26362500 UR - https://doi.org/10.64898/2026.09.12.26362500 ER -
APA
N, C., C, T., D, B., J, P., K, Z., J, C., C, L., A, M., J, B., L, B., B, M., RJ, G., V, W., J, W., KJ, G., JA, S., & Investigators, T. (2026). An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial.. medRxiv : the preprint server for health sciences. https://doi.org/10.64898/2026.09.12.26362500
Source records
- pubmed · retrieved 2026-09-26T00:32:45.206Z